Seek Returns

GMAB vs. RVTY: Genmab vs. Revvity Stock Comparison

How do Genmab (GMAB) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Genmab (GMAB) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Revvity (RVTY) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Genmab (GMAB) and Revvity (RVTY)
Profile ItemGMABRVTY
NameGenmab A/S American Depositary SharesRevvity Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization32.98 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 1, 2009February 21, 1973
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

GMAB
RVTY
GSPC
Loading price history…
Genmab (GMAB) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Genmab (GMAB) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Genmab (GMAB) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
Total Return (1Y)91.17%76.75%
Total Return (3Y, Annualized)20.70%24.22%
Total Return (5Y, Annualized)3.98%-1.48%

Risk Profile

Drawdown History

GMAB
RVTY
GSPC
Loading price history…
Genmab (GMAB) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Genmab (GMAB) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
Volatility (1Y, Annualized)45.68%40.22%
Beta (5Y)0.721.07
Max Drawdown (5Y)-61.79%-59.01%
Avg. Volume (3M)4.09M1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GMAB and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
Sharpe Ratio (1Y)1.901.80
Sortino Ratio (1Y)3.822.90

Profitability

ROE (TTM)

Genmab (GMAB) at 12.07% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for GMAB.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max
109.18%
GMAB
12.07%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Genmab (GMAB) at 16.97% and Revvity (RVTY) at 8.61% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max
18.05%
GMAB
16.97%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Genmab (GMAB) at 37.15% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max
83.12%
GMAB
37.15%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
ROE (TTM)12.07%3.45%
ROA (TTM)8.24%2.54%
Net Margin (TTM)16.97%8.61%
Operating Margin (TTM)37.15%17.06%
Gross Margin (TTM)92.67%55.91%

Growth

Revenue Growth

Both Genmab (GMAB) at 19.19% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Genmab (GMAB) at -9.23% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
Revenue Growth (YoY)19.19%3.67%
Revenue Growth (3Y CAGR)21.23%-4.82%
EPS Growth (YoY)-9.23%-5.91%
EPS Growth (3Y CAGR)8.48%-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GMAB
2.45
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revvity (RVTY) at 0.38 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max
1.42
GMAB
0.82
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
Current Ratio (MRQ)2.452.65
Debt / Equity (MRQ)0.820.38
Net Debt / EBITDA2.452.43

Dividends

Dividend Yield (TTM)

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
Dividend Yield (TTM)0.00%0.19%
Dividend Payout Ratio (TTM)0.00%13.40%

Valuation

P/E Ratio (TTM)

Both Genmab (GMAB) at 45.84 and Revvity (RVTY) at 68.94 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max
85.34
GMAB
45.84
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Genmab (GMAB) at 7.68 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max
58.18
Q3
25.77
GMAB
7.68
Median
7.30
Q1
3.01
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Genmab (GMAB) at 5.36 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max
13.53
Q3
6.54
GMAB
5.36
Median
3.25
Q1
1.69
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
Genmab (GMAB) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Genmab (GMAB) and Revvity (RVTY)
MetricGMABRVTY
P/E Ratio (TTM)45.8468.94
P/S Ratio (TTM)7.685.88
P/B Ratio (MRQ)5.362.39
Free Cash Flow Yield (TTM)2.59%3.62%